Merck KGaA 2024 AR2
The report highlights the Merck Group's return to growth in fiscal 2024, with net sales increasing to €21.2 billion and EBITDA pre rising to €6.1 billion. The company made significant progress toward its sustainability goals, reducing direct (Scope 1) and indirect (Scope 2) greenhouse gas emissions by 26% compared to the previous year. Key strategic developments included the acquisitions of Mirus Bio, Unity-SC, and Hub Organoids, alongside the initiated divestment of the Surface Solutions business unit. Additionally, the company maintained its commitment to gender equity, with women holding 39% of leadership positions globally.
Company: Merck KGaA
Sector: Health Care
Country: Germany
Year: 2024
Type: AR2
Pages: 540
Merck KGaA
Annual Report
The report highlights the Merck Group's return to growth in fiscal 2024, with net sales increasing to €21.2 billion and EBITDA pre rising to €6.1 billion. The company made significant progress toward its sustainability goals, reducing direct (Scope 1) and indirect (Scope 2) greenhouse gas emissions by 26% compared to the previous year. Key strategic developments included the acquisitions of Mirus Bio, Unity-SC, and Hub Organoids, alongside the initiated divestment of the Surface Solutions business unit. Additionally, the company maintained its commitment to gender equity, with women holding 39% of leadership positions globally.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees